[go: up one dir, main page]

WO2014008379A3 - Diamine and meglumine salt forms of fatty acids - Google Patents

Diamine and meglumine salt forms of fatty acids Download PDF

Info

Publication number
WO2014008379A3
WO2014008379A3 PCT/US2013/049290 US2013049290W WO2014008379A3 WO 2014008379 A3 WO2014008379 A3 WO 2014008379A3 US 2013049290 W US2013049290 W US 2013049290W WO 2014008379 A3 WO2014008379 A3 WO 2014008379A3
Authority
WO
WIPO (PCT)
Prior art keywords
diamine
fatty acids
salt forms
meglumine salt
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/049290
Other languages
French (fr)
Other versions
WO2014008379A2 (en
Inventor
Banavara L. Mylari
Frank C. SCIAVOLINO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,667 external-priority patent/US20140011814A1/en
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Publication of WO2014008379A2 publication Critical patent/WO2014008379A2/en
Publication of WO2014008379A3 publication Critical patent/WO2014008379A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are diamine salts of eicosapentaenoic acid and docosahexaenoic acid, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and the uses of such compounds as agents for treating dyslipidemia, cardiovascular diseases such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke and obesity.
PCT/US2013/049290 2012-07-06 2013-07-03 Diamine and meglumine salt forms of fatty acids Ceased WO2014008379A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261668582P 2012-07-06 2012-07-06
US201261668517P 2012-07-06 2012-07-06
US201261668512P 2012-07-06 2012-07-06
US61/668,512 2012-07-06
US61/668,517 2012-07-06
US61/668,582 2012-07-06
US201261670384P 2012-07-11 2012-07-11
US61/670,384 2012-07-11
US13/841,667 2013-03-15
US13/841,667 US20140011814A1 (en) 2012-07-06 2013-03-15 Diamine and meglumine salt forms of fatty acids

Publications (2)

Publication Number Publication Date
WO2014008379A2 WO2014008379A2 (en) 2014-01-09
WO2014008379A3 true WO2014008379A3 (en) 2014-02-20

Family

ID=49882605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/049290 Ceased WO2014008379A2 (en) 2012-07-06 2013-07-03 Diamine and meglumine salt forms of fatty acids

Country Status (1)

Country Link
WO (1) WO2014008379A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111911A1 (en) 2016-12-14 2018-06-21 Ecolab USA, Inc. Quaternary cationic polymers
WO2019241056A1 (en) 2018-06-12 2019-12-19 Ecolab Usa Inc. Quaternary cationic surfactants and polymers for use as release and coating modifying agents in creping and tissue papers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033155A1 (en) * 1995-04-20 1996-10-24 Scotia Holdings Plc Fatty acid derivatives
WO2007091070A1 (en) * 2006-02-07 2007-08-16 Universitetet I Oslo Omega 3
WO2008053331A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033155A1 (en) * 1995-04-20 1996-10-24 Scotia Holdings Plc Fatty acid derivatives
WO2007091070A1 (en) * 2006-02-07 2007-08-16 Universitetet I Oslo Omega 3
WO2008053331A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA accession no. 26:11535 *
DATABASE CA accession no. 47:276352 *
MACKIE S.J. ET AL.: "Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: In vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 75, 2006, pages 367 - 373 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides

Also Published As

Publication number Publication date
WO2014008379A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
CR20150020A (en) 5-AMINOTETRAHYDROQUINOLIN-2-NEW CARBOXYLIC ACIDS AND THEIR USE
CO6771409A2 (en) Substituted 1-benzylcycloalkylcarboxylic acids and their use
EA201591050A1 (en) IMIDAZOPIRIDINE CONNECTIONS
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
ZA201403111B (en) Processes, products, and compositions having tetraalkylguanidine salt of aromatic carboxylic acid
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
IL234133B (en) Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
WO2014205451A3 (en) Compositions and methods for modulation of target nucleic acids
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
TW201613932A (en) Organic compounds
WO2016098131A3 (en) Improved method for the synthesis of ferric oraganic compounds
IN2015KN00076A (en)
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2014008379A3 (en) Diamine and meglumine salt forms of fatty acids
WO2012112841A3 (en) [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
MX2015007885A (en) Pharmaceutical compounds.
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
TN2014000106A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2014083575A3 (en) Improved process for the preparation of boceprevir intermediate
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
WO2013044176A3 (en) Methods and compositions for the treatment of ischemic stroke
WO2016027211A3 (en) Process for the preparation of cinacalcet and its pharmaceutically acceptable salts
WO2016044433A3 (en) Metformin derivatives
WO2012045550A3 (en) A skin lightening composition
JP2012041294A5 (en)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13812739

Country of ref document: EP

Kind code of ref document: A2